Pular para o conteúdo
Menu
Mix Vale

Novo Nordisk wants to include Wegovy in the SUS after starting a dispute with pharmacy chains

Beatriz
Por 2 min de leitura
Compartilhe
Novo Nordisk
Foto: Novo Nordisk - JHVEPhoto / Shutterstock.com

The Danish pharmaceutical company Novo Nordisk has outlined as one of its main strategic objectives the incorporation of Wegovy, a medicine aimed at treating obesity, into the Unified Health System (SUS). The move to expand access to treatment occurs in parallel to a period of commercial friction and tensions with large pharmacy chains in Brazil due to profit margins and distribution policies.

Publicidade

Dissatisfaction with large drugstore chains

Tensions between the manufacturer of Ozempic and large Brazilian pharmacy chains have intensified in recent months. The main reason for the friction is the excessively tight profit margin that Novo Nordisk passes on to pharmaceutical retailers when selling high-demand medicines.

Executives in the sector complain that the sales model imposed by the multinational reduces the profitability of stores. Drugstore chains argue that they bear high operational costs of cold storage, strict logistics for biological products and financial card fees, receiving in return a financial return considered insufficient to sustain the sales operation of these drugs.

Publicidade

The financial challenge of taking Wegovy to the SUS

To enable Wegovy to enter the public health network, Novo Nordisk will need to undergo a rigorous evaluation process by the National Commission for the Incorporation of Technologies into the SUS (Conitec). The main obstacle is the budgetary impact for the Brazilian government, which requires in-depth price discount negotiations for large-scale purchases.

  • Wegovy’s average retail price:from R$2,200 to R$2,400 per month, depending on the dosage.
  • Estimated eligible population:more than 20 million Brazilians with moderate to severe obesity.
  • Tax impact:potential spending of billions of reais annually for the Ministry of Health, if there is no agreement on a spending cap or substantial discount.
Wegovy
Wegovy – Photo: Aguadeluna / Shutterstock.com

Long-term strategy and public health

The inclusion of the medicine in the SUS is seen by Novo Nordisk as essential to consolidate the treatment of a chronic disease that affects around 22% of the Brazilian adult population. The company is betting on the thesis that treating obesity in the public network generates long-term savings for the State, as it reduces hospitalizations, surgeries and ongoing treatments for serious associated complications, such as type 2 diabetes, heart attacks and strokes.

Publicidade

Beatriz Lima é colaboradora da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2024.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto